Literature DB >> 2988730

The Vancouver Lymphadenopathy-AIDS Study: 3. Relation of HTLV-III seropositivity, immune status and lymphadenopathy.

W J Boyko, M T Schechter, E Jeffries, B Douglas, M Maynard, M O'Shaughnessy.   

Abstract

In a study of 394 homosexual men recruited at the primary care level the prevalence of antibody to human T-lymphotropic retrovirus (HTLV-III) was higher among those with lymph node enlargement than among controls. The degree of abnormal immune function, as shown by abnormalities in immunoglobulin levels, immune complex activity and T-lymphocyte subsets, was correlated with the extent of lymphadenopathy. A similar pattern of immunologic abnormality was associated with seropositivity for HTLV-III antibody. However, HTLV-III seropositivity was the major determinant of immune function after adjustment for lymph node status. The results suggest that the immune dysfunction seen in patients with lymphadenopathy is due for the most part to the high prevalence of HTLV-III seropositivity in these populations. Lymphadenopathy, in many subjects, may in fact represent a physical sign of a stabilized compensated homeostatic host response. Factors responsible for severe immune decompensation associated with acquired immune deficiency syndrome (AIDS) may best be sought by prospective study of HTLV-III seropositive asymptomatic patients or those with stable persistent generalized lymphadenopathy and relatively normal immune function.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2988730      PMCID: PMC1346063     

Source DB:  PubMed          Journal:  Can Med Assoc J        ISSN: 0008-4409            Impact factor:   8.262


  27 in total

1.  Antibodies to HTLV-III associated antigens in populations exposed to AIDS virus in France.

Authors:  D Mathez; J Leibowitch; S Matheron; A G Saimot; P Catalan; D Zaguri
Journal:  Lancet       Date:  1984-08-25       Impact factor: 79.321

2.  Seroepidemiology of HTLV-III antibody in Danish homosexual men: prevalence, transmission, and disease outcome.

Authors:  M Melbye; R J Biggar; P Ebbesen; M G Sarngadharan; S H Weiss; R C Gallo; W A Blattner
Journal:  Br Med J (Clin Res Ed)       Date:  1984-09-08

3.  Persistent generalized lymphadenopathy in homosexual men: clinical, pathological and immunologic characteristics.

Authors:  N J Gilmore; J F Prchal; S Jothy
Journal:  Can Med Assoc J       Date:  1983-11-01       Impact factor: 8.262

4.  Selective tropism of lymphadenopathy associated virus (LAV) for helper-inducer T lymphocytes.

Authors:  D Klatzmann; F Barré-Sinoussi; M T Nugeyre; C Danquet; E Vilmer; C Griscelli; F Brun-Veziret; C Rouzioux; J C Gluckman; J C Chermann
Journal:  Science       Date:  1984-07-06       Impact factor: 47.728

5.  Persistent diffuse lymphadenopathy in homosexual men: endpoint or prodrome?

Authors:  D I Abrams; B J Lewis; J H Beckstead; C A Casavant; W L Drew
Journal:  Ann Intern Med       Date:  1984-06       Impact factor: 25.391

6.  Studies in homosexual patients with and without lymphadenopathy. Relationships to the acquired immune deficiency syndrome.

Authors:  R D deShazo; J P Penico; G A Pankey; J A Nordberg; J L Newton; B Bozelka; L M Cortez; J R Dalovisio
Journal:  Arch Intern Med       Date:  1984-06

7.  Seroepidemiological studies of human T-lymphotropic retrovirus type III in acquired immunodeficiency syndrome.

Authors:  B Safai; M G Sarngadharan; J E Groopman; K Arnett; M Popovic; A Sliski; J Schüpbach; R C Gallo
Journal:  Lancet       Date:  1984-06-30       Impact factor: 79.321

8.  Detection of IgG antibodies to lymphadenopathy-associated virus in patients with AIDS or lymphadenopathy syndrome.

Authors:  F Brun-Vezinet; C Rouzioux; F Barre-Sinoussi; D Klatzmann; A G Saimot; W Rozenbaum; D Christol; J C Gluckmann; L Montagnier; J C Chermann
Journal:  Lancet       Date:  1984-06-09       Impact factor: 79.321

9.  Critical analysis of T cell subset and function evaluation in patients with persistent generalized lymphadenopathy in groups at risk for AIDS.

Authors:  M Cavaille-Coll; A Messiah; D Klatzmann; W Rozenbaum; D Lachiver; S Kernbaum; E Brisson; F Chapuis; C Blanc; P Debre
Journal:  Clin Exp Immunol       Date:  1984-09       Impact factor: 4.330

10.  Serological analysis of a subgroup of human T-lymphotropic retroviruses (HTLV-III) associated with AIDS.

Authors:  J Schüpbach; M Popovic; R V Gilden; M A Gonda; M G Sarngadharan; R C Gallo
Journal:  Science       Date:  1984-05-04       Impact factor: 47.728

View more
  8 in total

1.  Human T-lymphotropic virus: exposure and prognosis.

Authors:  C L Soskolne; D Heyland; E Phillips
Journal:  CMAJ       Date:  1986-03-15       Impact factor: 8.262

2.  The Vancouver Lymphadenopathy-AIDS Study: 6. HIV seroconversion in a cohort of homosexual men.

Authors:  M T Schechter; W J Boyko; B Douglas; B Willoughby; A McLeod; M Maynard; K J Craib; M O'Shaughnessy
Journal:  CMAJ       Date:  1986-12-15       Impact factor: 8.262

3.  Relation of HTLV-III seropositivity and lymphadenopathy.

Authors:  E Jeffries; W J Boyko; B Willoughby; P D Constance; B Wiggs; M O'Shaughnessy; F R Sharp
Journal:  Can Med Assoc J       Date:  1985-07-15       Impact factor: 8.262

4.  Oral manifestations of human immunodeficiency virus infection.

Authors:  J B Epstein; R G Mathias
Journal:  Can Fam Physician       Date:  1988-08       Impact factor: 3.275

5.  Effects of anticoagulant, processing delay, and assay method (branched DNA versus reverse transcriptase PCR) on measurement of human immunodeficiency virus type 1 RNA levels in plasma.

Authors:  L M Kirstein; J W Mellors; C R Rinaldo; J B Margolick; J V Giorgi; J P Phair; E Dietz; P Gupta; C H Sherlock; R Hogg; J S Montaner; A Muñoz
Journal:  J Clin Microbiol       Date:  1999-08       Impact factor: 5.948

6.  Increased interleukin-2 receptor expression after mitogen stimulation on CD4- and CD8-positive lymphocytes and decreased interleukin-2 production in HTLV-III antibody-positive symptomatic individuals.

Authors:  P C Creemers; M O'Shaughnessy; W J Boyko
Journal:  Immunology       Date:  1986-12       Impact factor: 7.397

7.  Diagnostic utility of lymphocyte subset analysis in AIDS case finding.

Authors:  W J Boyko; M T Schechter; A MacLeod; B Douglas; M Maynard; R Sharp; B Wiggs
Journal:  CMAJ       Date:  1986-05-01       Impact factor: 8.262

8.  The Vancouver Lymphadenopathy-AIDS Study: 7. Clinical and laboratory features of 87 cases of primary HIV infection.

Authors:  W J Boyko; M T Schechter; K J Craib; B Willoughby; B Douglas; P Sestak; W A McLeod; M O'Shaughnessey
Journal:  CMAJ       Date:  1987-07-15       Impact factor: 8.262

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.